Hosted on MSN

GD2 CAR T treatment induces durable remissions in high-risk neuroblastoma

From Bambino Gesù Children's Hospital in Rome comes a report that a third-generation CAR T cell therapy targeting GD2, designated GD2–CART01, induced durable remissions and long-term survival in ...
Nasdaq

Y-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research Meeting

Y-mAbs announces GD2-SADA clinical trial presentation for treating GD2-expressing tumors at the Advances in Neuroblastoma Research Meeting. Y-mAbs Therapeutics, Inc. has announced the presentation of ...
Nasdaq

Y-mAbs Presents GD2-SADA Pharmacokinetics Data At SNMMI And ACNM Annual Meeting

(RTTNews) - Y-mAbs Therapeutics, Inc. (YMAB), a commercial-stage biopharmaceutical company presented preclinical and translational pharmacokinetics or PK data of GD2-SADA at the 2025 SNMMI Mid-Winter ...
ascopubs.org

Preclinical characterization of pretargeted radioimmunotherapy (PRIT) with GD2-SADA, a self-assembling and disassembling bispecific fusion protein.

Pharmacogenomic diversity of clinically significant cancer treatment biomarkers in ancestrally diverse US population. Effect of targeting FAK by ifebemtinib and immunogenic cell death of Kras ...